OptumRx has agreed to pay $1.86 million to settle a class action lawsuit alleging the company violated the Telephone Consumer Protection Act (TCPA) by placing prerecorded clinical adherence calls to cellular phones without obtaining prior express written consent from recipients. The case, Patterson v. OptumRx, Inc. (S.D.
Ind.), covers calls made between April 20, 2020 and October 22, 2025. If you received unwanted robocalls from OptumRx during this period—particularly calls about medication refills, clinical adherence programs, or health coaching—you may be entitled to a cash payment between $72 and $135 per claim, depending on how many valid claims are submitted to the settlement fund. The settlement includes both a monetary payment to affected consumers and court-ordered changes to how OptumRx conducts its calling practices.
Table of Contents
- What TCPA Violations Did OptumRx Commit and Why Does It Matter?
- Who Is Eligible to Claim Payment Under This Settlement?
- How Much Money Will the Settlement Distribute and What Is Your Per-Claim Payout?
- How Do You File a Claim and What Is the Deadline?
- What Happens If Your Claim Is Denied or Disputed?
- What Changes Will OptumRx Have to Make Going Forward?
- How Does This Settlement Fit Into the Broader Landscape of TCPA Litigation?
What TCPA Violations Did OptumRx Commit and Why Does It Matter?
OptumRx, a major pharmacy benefits manager owned by Unitedhealth Group, allegedly violated the Telephone Consumer Protection Act by placing artificial or prerecorded voice calls to people’s cell phones without first obtaining their explicit written permission. The TCPA, passed in 1991, strictly limits how companies can use robocalls and restricts calling cell phones using automated systems without prior consent. OptumRx’s calls were ostensibly for legitimate health purposes—clinical adherence outreach, medication reminders, and health coaching—but the law does not carve out an exception for beneficial calls; the consent requirement applies regardless of the call’s content or intent.
The distinction matters because many companies assume that “helpful” calls don’t require consent, or that existing business relationships (like dispensing a medication) automatically grant permission to call about related services. That assumption is incorrect under TCPA. OptumRx did not obtain separate, prior express written consent to place robocalls to cell phones, which is what the law requires. This distinction explains why OptumRx, a company providing legitimate healthcare services, still faced a $1.86 million lawsuit.
Who Is Eligible to Claim Payment Under This Settlement?
The class includes all non-customers and non-account holders who received prerecorded clinical adherence calls on their cellular phones or VOIP lines between April 20, 2020 and October 22, 2025. Importantly, the class is not limited to OptumRx customers or people covered by health plans that use OptumRx as their pharmacy benefits manager. Rather, it covers people who received these calls but did not have a direct relationship with OptumRx—essentially, people who received unwanted calls from a company they never agreed to hear from.
However, if you were an active OptumRx customer or account holder during the call period, you are explicitly excluded from the settlement class. The settlement treats customers who may have consented to OptumRx communications as a separate group. If you actively use OptumRx’s services and received these calls, you may have other legal remedies, but you cannot participate in this specific settlement as a class member.
How Much Money Will the Settlement Distribute and What Is Your Per-Claim Payout?
The total settlement fund is $1.86 million, but your individual payment will depend on the number of valid claims filed. The settlement estimate projects payments between $72 and $135 per participating class member. This range exists because the settlement divides the fund among all valid claimants—more claims mean smaller individual payments; fewer claims mean larger individual payments.
For example, if 15,000 valid claims are submitted, each person might receive approximately $100 to $120 per claim (after deductions for administration costs and attorney fees, which are capped at 33.33% of the fund). The settlement also requires OptumRx to pay approximately $1.9 million in separate costs (according to some reporting), covering attorneys’ fees, settlement administration, and claims processing. This means OptumRx’s total financial obligation is closer to $3.76 million when all expenses are included. Unlike some settlements where payment amounts are fixed per person, this settlement uses a claims-based approach: you receive payment only if you submit a claim by the deadline.
How Do You File a Claim and What Is the Deadline?
To participate in this settlement, you must submit a claim by February 4, 2026. Claims can be filed at the official settlement website, https://optumrxtcpaclassactionSettlement.com/, where you will need to provide basic information about yourself and details about the calls you received (such as approximate dates, phone number called, or content of the calls if you remember them). The settlement administrator will use this information to verify your eligibility and process your payment. The key comparison here is between filing early and filing at the last minute.
Filing early gives the settlement administrator more time to verify your claim and resolve any issues before the deadline passes, whereas waiting until January or early February risks missing the window entirely if your claim is incomplete or requires clarification. There is no penalty for filing early, so if you believe you received OptumRx robocalls during the relevant period, file your claim as soon as possible. The final fairness hearing—where a federal judge will approve the settlement—is scheduled for March 31, 2026 at 9:00 a.m. ET.
What Happens If Your Claim Is Denied or Disputed?
If the settlement administrator denies your claim or you disagree with the amount awarded, you have the right to object before the final fairness hearing. Objections must be submitted in writing by a specific deadline (typically 30-45 days before the fairness hearing) and must explain why you believe your claim should be approved or why the settlement terms are unfair. However, objecting does not guarantee your claim will be reconsidered—the judge decides whether your objection has merit.
A critical limitation of this settlement is that the $1.86 million fund is capped, meaning once the money runs out, additional claimants beyond what the fund can pay will not receive compensation. If an unusually large number of people file valid claims, the per-claim payout will decrease accordingly. Conversely, if fewer people claim than anticipated, individual payments could increase. This creates an incentive to file promptly: delayed claims risk being submitted after funds are depleted, though in practice the settlement administrator works to ensure all valid claims filed by the deadline are paid from the fund before distributions occur.
What Changes Will OptumRx Have to Make Going Forward?
Beyond the monetary settlement, OptumRx has agreed to implement injunctive relief—court-ordered changes to its calling practices. These include obtaining prior express written consent before placing any prerecorded calls to cell phones, maintaining an internal do-not-call list, and implementing compliance monitoring procedures. The settlement also requires OptumRx to train employees involved in outbound calling and to provide regular compliance reports to the plaintiff’s attorneys and the court for a specified period.
This injunctive component is as important as the money to settlement class members, because it aims to prevent future TCPA violations. OptumRx is now bound by a court order, meaning if the company fails to obtain proper consent before placing robocalls in the future, it risks contempt of court and additional litigation. The settlement does not, however, prevent OptumRx from contacting people entirely—it simply requires the company to first obtain explicit written permission to do so.
How Does This Settlement Fit Into the Broader Landscape of TCPA Litigation?
The OptumRx settlement is part of a larger wave of TCPA lawsuits targeting healthcare companies, insurance providers, and pharmacy benefits managers that place high-volume robocalls. UnitedHealth Group, OptumRx’s parent company, has faced multiple TCPA settlements in recent years, reflecting the reality that large healthcare organizations often maintain massive calling campaigns to reach patients about medications, preventive care, and coverage information—all of which generate substantial legal exposure under the TCPA.
The trend suggests that companies in healthcare and insurance are increasingly being held accountable for assuming they can place robocalls without separate consent, even when calls relate to legitimate health purposes. Future settlements and judgments may raise the compliance bar even further, particularly if class actions succeed in establishing that healthcare-related calls receive no special exemption from TCPA rules.